Literature DB >> 22812712

Targeting somatostatin receptors using in situ-bioconjugated fluorescent nanoparticles.

Varun K A Sreenivasan1, Eun J Kim, Ann K Goodchild, Mark Connor, Andrei V Zvyagin.   

Abstract

AIM: The author's group report, for the first time, on the development of a quantum dot (QD)-based fluorescent somatostatin (somatotropin release-inhibiting factor [SRIF]) probe that enables specific targeting of somatostatin receptors. Receptor-mediated endocytosis of SRIF was imaged using this probe. MATERIALS &
METHODS: Biotinylated SRIF-analog (SRIF-B) and streptavidin (Sav)-coated QDs were used for the probe synthesis. A dye-labeled streptavidin complex was used to evaluate the effect of Sav binding on the activity of SRIF-B.
RESULTS: A preconjugated probe of the form SRIF-B:Sav-QD, was inactive and unable to undergo receptor-mediated endocytosis. An alternative in situ bioconjugation strategy, where SRIF-B and Sav-QD were added in two consecutive steps, enabled visualization of the receptor-mediated endocytosis. The process of Sav binding appeared to be responsible for the inactivity in the first case.
CONCLUSION: The in situ two-step bioconjugation strategy allowed QDs to be targeted to somatostatin receptors. This strategy should enable flexible fluorescent tagging of SRIF for the investigation of molecular trafficking in cells and targeted delivery in live animals.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22812712     DOI: 10.2217/nnm.12.42

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  2 in total

1.  Targeting of somatostatin receptors expressed in blood cells using quantum dots coated with vapreotide.

Authors:  Ahmed A H Abdellatif; Heba A Abou-Taleb; Ahmed A Abd El Ghany; Ilka Lutz; Abdellatif Bouazzaoui
Journal:  Saudi Pharm J       Date:  2018-07-20       Impact factor: 4.330

2.  Quantitative imaging of single upconversion nanoparticles in biological tissue.

Authors:  Annemarie Nadort; Varun K A Sreenivasan; Zhen Song; Ekaterina A Grebenik; Andrei V Nechaev; Vladimir A Semchishen; Vladislav Y Panchenko; Andrei V Zvyagin
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.